OVB — Ovoca Bio Income Statement
0.000.00%
Last trade - 00:00- £1.04m
- -£1.46m
- 19
- 68
- 45
- 36
Annual income statement for Ovoca Bio, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2.28 | 2.53 | 5.33 | 5.58 | 5.1 |
| Operating Profit | -2.28 | -2.53 | -5.33 | -5.58 | -5.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.9 | -2.32 | -5.25 | -5.61 | -5.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.9 | -2.32 | -5.25 | -5.61 | -5.1 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -1.57 | -2.34 | -5.47 | -5.61 | -4.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.57 | -2.34 | -5.47 | -5.61 | -4.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.018 | -0.028 | -0.064 | -0.065 | -0.01 |
| Dividends per Share |